Search
Sodium tetradecyl sulfate
go.drugbank.com/drugs/DB00464ApprovedAn anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.
Categories: Compounds used in a research, industrial, or household settingInfluenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15788ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeIndium In-111 pentetreotide
go.drugbank.com/drugs/DB11835ApprovedIndium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
Mixtures: Kit for the Preparation of Indium In 111 PentetreotideSynonyms: Indium In 111 Pentreotide, Indium In 111 pentetreotideTechnetium Tc-99m pyrophosphate
go.drugbank.com/drugs/DB09165ApprovedIt has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. … A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process.
Categories: Compounds used in a research, industrial, or household settingInfluenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14385ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeMolsidomine
go.drugbank.com/drugs/DB09282ApprovedWithdrawnInterestingly, it is being studied as being a preventive measure in cerebral infarction [A31932]. … Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones.
Categories: Vasodilators Used in Cardiac DiseasesTalquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigational[L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]
Synonyms: SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED ANUdenafil
go.drugbank.com/drugs/DB06267ApprovedUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. … It is not yet approved for use in the U.S., E.U., or Canada.
Categories: Drugs Used in Erectile DysfunctionInfluenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10600ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing